Viridian Therapeutics, Inc. (VRDN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Viridian Therapeutics, Inc. (VRDN) closed at USD 18.38 on 2026-10-14, a change of -20.7 % over the past year, with a market capitalization of USD 2.22B.

Viridian Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Viridian Therapeutics, Inc. key figures

Previous close

USD 18.38 (2026-10-14)

1-year change

-20.7 %

Market cap

USD 2.22B

Enterprise value

USD 1.58B

P/E ratio (trailing)

-5.37

P/E ratio (forward)

-7.10

EPS (trailing)

-3.64

EPS (forward)

-2.75

PEG ratio

n/a

Price to book

3.93

Revenue growth

278.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.90

Employees

252

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Viridian Therapeutics, Inc. and compare it with other stocks.